Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Piper Sandler Suspends Coupa Software Rating And Price Target

Piper Sandler Suspends Coupa Software Rating And Price Target

Piper Sandler analyst Brent Bracelin suspends Coupa Software (NASDAQ:COUP) rating and price target.

byBenzinga Newsdesk

December 13, 2022

1 minute read

Piper Sandler analyst Brent Bracelin suspends Coupa Software (NASDAQ:COUP) rating and price target.

Keybanc Initiates Coverage On Doximity with Sector Weight Rating

By Benzinga Newsdesk

September 16, 5:23 AM

Keybanc initiates coverage on Doximity (NYSE:DOCS) with a Sector Weight rating.

DOCS

What’s Going On With AutoZone Stock?

By Adam Eckert

December 6, 10:44 AM

AutoZone Inc (NYSE: AZO) shares are trading slightly lower Tuesday after the company turned in third-quarter results that topped analyst expectations.

AZO

Symbotic Q3 EPS $(0.03), Sales $175.60M Up From $131.49M YoY

By Bill Haddad

August 1, 4:29 PM

Symbotic (NASDAQ:SYM) reported quarterly losses of $(0.03) per share. The company reported $175.60 million in sales this quarter. This is a 33.55 percent increase over sales of $131.49 million the same period last year.

SYM

Ultragenyx To Present Setrusumab Update At ASBMR 2023 Including New Data From Phase 2/3 Orbit Study In Osteogenesis Imperfecta

By Benzinga Newsdesk

October 9, 8:04 AM

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone

MREO

Piper Sandler Suspends Coupa Software Rating And Price Target

Related Posts

Keybanc Initiates Coverage On Doximity with Sector Weight Rating

What’s Going On With AutoZone Stock?

Symbotic Q3 EPS $(0.03), Sales $175.60M Up From $131.49M YoY

Ultragenyx To Present Setrusumab Update At ASBMR 2023 Including New Data From Phase 2/3 Orbit Study In Osteogenesis Imperfecta